Sclerotherapy Market

Market Overview: 

The global sclerotherapy market size reached USD 1.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.05% during 2025-2033. The growing prevalence of varicose veins and spider veins among individuals across the globe, rising demand for minimally invasive (MI) procedures, and technological advancements in sclerotherapy techniques are some of the major factors propelling the market.

Sclerotherapy is a minimally invasive (MI) procedure that is used to treat varicose veins and spider veins. It comprises injecting a solution directly into the affected veins and causing them to collapse and eventually fade away. It is an effective and safe treatment option with minimal side effects and a high success rate. As it assists in improving the appearance of the legs, reducing discomfort associated with varicose veins, and restoring proper blood flow, the demand for sclerotherapy is rising across the globe.

At present, the increasing adoption of sclerotherapy to reduce the visibility of varicose veins or spider veins on legs is strengthening the growth of the market. In addition, the rising demand for sclerotherapy due to the improving societal beauty standards is offering a positive market outlook. Apart from this, the increasing awareness about the availability of treatments for varicose veins and spider veins, along with the improving healthcare facilities around the world, is contributing to the growth of the market. In line with this, the growing demand for sclerotherapy due to the increasing consciousness about appearance among individuals across the globe is positively influencing the market. Furthermore, the rising adoption of sclerotherapy on account of the inflating income level of individuals is offering lucrative growth opportunities to industry players. 

Sclerotherapy Market Trends/Drivers:

Rising prevalence of varicose veins and spider veins

There is a rise in the prevalence of varicose veins and spider veins among the masses across the globe on account of sedentary lifestyles, obesity, and genetic predisposition. Varicose veins and spider veins are common among the geriatric population, as the valves of their veins get weak in old age. People suffering from obesity have a higher chance of developing vein-related issues. In addition, the rising adoption of sclerotherapy solutions to reduce the risks of the formation of these vein abnormalities is contributing to the growth of the market. Furthermore, people are increasingly preferring effective and convenient treatment options like sclerotherapy to enhance the quality of their life and prevent pain and swelling.

Increasing demand for minimally invasive procedures

Sclerotherapy is a MI procedure that efficiently treats vein-related disorders among individuals. People are rapidly accepting sclerotherapy, as it has shorter recovery time, reduced scarring, and lower healthcare costs compared to traditional surgical interventions. Moreover, there is an increase in the demand for MI treatments that can address varicose veins or spider veins without the need for extensive surgery and incisions on the human body. Sclerotherapy is an effective, time saving, and less invasive alternative to other treatment options for these diseases. Apart from this, healthcare providers are rapidly utilizing sclerotherapy, as it is convenient and assists in enhancing patient satisfaction by reducing the number of stays in healthcare facilities.

Technological advancements in sclerotherapy techniques

Rising advancements in sclerotherapy techniques and technologies aid in improving efficacy and safety. There are various advancements in imaging technologies, such as ultrasound and Doppler imaging, that assist in enhancing the diagnosis and evaluation of vein conditions. These imaging techniques also benefit healthcare professionals in assessing the severity and extent of the venous disease and allow improved decision-making. The wide availability of advanced imaging technologies with increased accuracy is positively influencing the market. Apart from this, advancement in foam sclerotherapy enhances the contact between the sclerosant and the vein wall that provides improved results. These technological advancements related to sclerotherapy provide enhanced treatment outcomes, which is contributing to the growth of the market. Furthermore, various manufacturers are developing more advanced and user-friendly equipment and instruments for high accessibility.

Sclerotherapy Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global sclerotherapy market report, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on type and agent.

Breakup by Type:

• Ultrasound Sclerotherapy
• Liquid Sclerotherapy
• Foam Sclerotherapy
   

Liquid sclerotherapy represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the type. This includes ultrasound sclerotherapy, liquid sclerotherapy, and foam sclerotherapy. According to the report, liquid sclerotherapy represented the largest segment. It involves the injection of a liquid sclerosing agent into the affected veins. The sclerosing agent irritates the vein walls, causing them to collapse and seal off. In addition, the increasing adoption of liquid sclerotherapy for treating smaller varicose veins and spider veins is propelling the growth of the market. 

Ultrasound sclerotherapy is a technique that utilizes ultrasound imaging to guide the injection of the sclerosing agent into the affected veins. It allows for precise targeting and delivery of the sclerosing agent that aids in improving the accuracy and effectiveness of the treatment. The rising utilization of ultrasound sclerotherapy for treating larger varicose veins is contributing to the growth of the market.

Foam sclerotherapy involves the creation of a foam mixture by combining a liquid sclerosing agent with air or gas. Moreover, the rising utilization of foam sclerotherapy, as it improves visibility during treatment, is bolstering the growth of the market. 

Breakup by Agent:

• Detergents
• Chemical Irritants
• Osmotic Agents
   

Detergents accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the agent. This includes detergents, chemical irritants, and osmotic agents. According to the report, detergents represented the largest segment. Polidocanol (polidocanol foam) and sodium tetradecyl sulfate (STS) are commonly used detergent sclerosants that are widely used in sclerotherapy. They work by disrupting the endothelial lining of the veins and causing them to collapse and seal off. Detergents are effective in treating both small spider veins and larger varicose veins.

Chemical irritants, such as hypertonic saline or chromated glycerin, are another type of sclerosing agent used in sclerotherapy. These agents work by causing irritation and inflammation in the vein walls, leading to their closure. The rising utilization of chemical irritants for treating smaller spider veins is contributing to the growth of the market.

Osmotic agents, such as concentrated glucose or glycerol, are used in sclerotherapy to induce osmotic dehydration of the vein walls. In addition, the rising employment of osmotic agents to shrink and close off the veins is strengthening the growth of the market. Osmotic agents are usually utilized to treat small spider veins and can be particularly effective in delicate areas, such as the face. 

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America exhibits a clear dominance, accounting for the largest sclerotherapy market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. 

North America held the biggest market share due to the increasing awareness about aesthetic treatments among individuals. Apart from this, the rising preference for non-surgical procedures among the masses in the region is propelling the growth of the market. In line with this, increasing advancements in healthcare infrastructure are supporting the growth of the market in the region. Besides this, the rising adoption of sclerotherapy due to the increasing Western culture and social media influence is strengthening the growth of the market.

Competitive Landscape:

Key players are rapidly developing improved sclerosing agents, injection techniques, and technologies in sclerotherapy. They are also focusing on launching products that provide enhanced efficacy and safety while minimizing side effects. Apart from this, major manufacturers are introducing specialized injection devices and ultrasound-guided systems to improve long-term outcomes, which is contributing to the growth of the market. In line with this, companies are engaging in partnerships and collaborations that benefit in conducting clinical studies and validating treatment outcomes. Besides this, they are investing in marketing and promotional activities to generate awareness about sclerotherapy treatments among healthcare professionals and potential patients by organizing campaigns and events. Additionally, industry players are focusing on adhering to regulatory guidelines to ensure the safety and efficacy of their products.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• AngioDynamics
• Boston Scientific Corporation
• Chemische Fabrik Kreussler & Co. GmbH
• Cook Medical, Inc.
• Medtronic PLC
• Mylan N.V
• Tianyu Chang’an Group

Sclerotherapy Market Report Scope:

Key Questions Answered in This Report:

• How has the global sclerotherapy market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global sclerotherapy market?
• What is the impact of each driver, restraint, and opportunity on the global sclerotherapy market?
• What are the key regional markets?
• Which countries represent the most attractive sclerotherapy market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the sclerotherapy market?
• What is the breakup of the market based on the agent?
• Which is the most attractive agent in the sclerotherapy market?
• What is the competitive structure of the global sclerotherapy market?
• Who are the key players/companies in the global sclerotherapy market?

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the sclerotherapy market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global sclerotherapy market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the sclerotherapy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.